Adimmune slides into red on rising R&D expenditure By Kao Shih-ching / Staff reporter Vaccine maker Adimmune Corp (國光生技) yesterday reported a net loss of NT$249 million (US$8.91 million) for last quarter, compared with a net profit of NT$1.24 billion in the fourth quarter of last year, due to rising research and development (R&D) expenses that involved a phase 1 clinical trial for its experimental vaccine against COVID-19. That translates into a loss per share of NT$0.58, widening from minus-NT$0.05 a year earlier. Revenue last quarter sank 98 percent year-on-year to NT$6.9 million due to a high comparison base last year, it said.